Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis B vaccine Bio Farma
- Development stage
- Phase 4
- Lead developer
- Bio Farma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant hepatitis B vaccine developed by PT Bio Farma is a biologic vaccine designed for active immunization against hepatitis B virus infection. The active ingredient is inactivated hepatitis B surface antigen (HBsAg) produced in yeast cells (*Hansenula polymorpha*) using recombinant DNA technology. PT Bio Farma has been producing this vaccine since 2000 to meet Indonesia's national immunization program requirements. The vaccine is presented as a whitish liquid and works by stimulating the immune system to produce antibodies against HBsAg. Clinical trials have demonstrated that the vaccine is immunogenic, well-tolerated, and safe, with studies evaluating different bulk antigen sources including those from the Serum Institute of India and Janssen Vaccine Corp.
- Brand names
- Hepatitis B Bio Farma
- Other names
- Recombinant Hepatitis B vaccineHepatitis B vaccine recombinant
02
Targets
B2GP1 (Beta-2-glycoprotein I)
Beyond the preview
Go deeper on recombinant hepatitis B vaccine Bio Farma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis B vaccine Bio Farma.